This 2000 narrative review by Hofbauer et al. synthesizes the newly discovered RANKL/RANK/OPG axis to explain how osteoclast formation and bone resorption are regulated at the molecular level. The central question: how do so many different hormones and cytokines ultimately control bone resorption through a coherent final pathway? The answer is a two-cytokine effector system whose ratio determines osteoclast pool size.
Every major cause of secondary osteoporosis in orthopedic patients — glucocorticoid therapy, estrogen deficiency, inflammatory arthritis. Converges on the same final molecular step: a shift in the RANKL/OPG ratio toward resorption.
When you prescribe or co-manage a patient on long-term steroids, this paper explains why bone loss begins within weeks: glucocorticoids suppress OPG by up to 90% and upregulate RANKL fourfold, and measurable serum OPG falls after just 4 weeks of therapy. This is the mechanistic basis for why bisphosphonates or RANKL inhibitors are indicated prophylactically in patients starting chronic steroid therapy.
Denosumab (Prolia) is a monoclonal antibody that mimics OPG by neutralizing RANKL. This paper is the foundational science behind why that drug works. Understanding that OPG is far more potent at blocking new osteoclast formation (effective at 1 ng/ml) than suppressing existing osteoclasts (requires 50-1000 ng/ml) also explains why antiresorptive therapy is most effective when started early.
The OPG knockout phenotype. Severe osteoporosis plus arterial calcification. Anticipates the clinical observation that osteoporosis and vascular calcification co-occur in aging women, a connection the authors explicitly note.
This 2000 narrative review by Hofbauer et al. synthesizes the newly discovered RANKL/RANK/OPG axis to explain how osteoclast formation and bone resorption are regulated at the molecular level. The central question: how do so many different hormones and cytokines ultimately control bone resorption through a coherent final pathway? The answer is a two-cytokine effector system whose ratio determines osteoclast pool size.
Every major cause of secondary osteoporosis in orthopedic patients — glucocorticoid therapy, estrogen deficiency, inflammatory arthritis. Converges on the same final molecular step: a shift in the RANKL/OPG ratio toward resorption.
When you prescribe or co-manage a patient on long-term steroids, this paper explains why bone loss begins within weeks: glucocorticoids suppress OPG by up to 90% and upregulate RANKL fourfold, and measurable serum OPG falls after just 4 weeks of therapy. This is the mechanistic basis for why bisphosphonates or RANKL inhibitors are indicated prophylactically in patients starting chronic steroid therapy.
Denosumab (Prolia) is a monoclonal antibody that mimics OPG by neutralizing RANKL. This paper is the foundational science behind why that drug works. Understanding that OPG is far more potent at blocking new osteoclast formation (effective at 1 ng/ml) than suppressing existing osteoclasts (requires 50-1000 ng/ml) also explains why antiresorptive therapy is most effective when started early.
The OPG knockout phenotype. Severe osteoporosis plus arterial calcification. Anticipates the clinical observation that osteoporosis and vascular calcification co-occur in aging women, a connection the authors explicitly note.